2025年8月23日，内江市第一人民医院风湿免疫科迎来学科发展的里程碑时刻。在医院党政领导班子的关心下，医院成功引进熊安吉博士作为学科新一代领军人才，并拥有了专属的独立病区和护理单元。风湿免疫科即将开启高质量、专业化发展的全新篇章。
奠基与传承：开拓学科建设起点
内江市第一人民医院风湿免疫科从无到有、由弱至强的发展历程，凝聚了包括邓梅主任医师等所有风湿免疫专家的心血与智慧。他们数十年来，潜心临床、深耕不辍，以精湛的医术为数以万计深受风湿疾病困扰的患者解除了病痛，奠定了科室良好的患者口碑;他们教书育人、甘为人梯，为风湿病专业培养了大批优秀的专业人才。
创新与引领：熊安吉博士扛起学科发展新旗
为延续学科优势，推动风湿免疫专业与技术再上新台阶，医院经过精心遴选，成功引进风湿免疫病学专家熊安吉博士担任科室新一代学术技术带头人。
熊安吉：风湿免疫科负责人
熊安吉博士毕业于四川大学华西医院，具有扎实的理论功底和丰富的临床科研经验，尤其在间质性肺疾病和疑难重症风湿免疫病的诊治方面造诣深厚。他的加入，为科室注入了新的活力与前沿的诊疗思维。在医院党政领导、职能部门和相关科室的大力支持下，熊安吉博士将会凭借其先进的理念、精湛的技术和开拓的精神，引领我院风湿免疫科在临床技术、人才培养和科学研究等方面实现全面跨越式发展，更好地满足区域内患者日益增长的高层次就医需求。
近五年来，熊安吉博士以第一作者或第一通讯作者且工作单位为第一单位发表 SCI21篇，累计影响因子近100分，有兴趣的朋友可以戳一戳了解哦~~
1. Luo W, Liu C, Zhang L, Tang J, Chen J, Zhao Y, Huang X, Zheng X, Chen L, Xie C, Wei X, Luo X, Xiong A. Characteristics and risk factors for infection in patients with ANCA-associated vasculitis: A systematic review and meta-analysis. Autoimmun Rev. 2025 Jan 31;24(2):103713. doi: 10.1016/j.autrev.2024.103713. Epub 2024 Nov 29. PMID: 39617249. (JCR分区：Q1)
2. Hu Z, Wang H, Huang J, Yang G, Luo W, Zhong J, Zheng X, Wei X, Luo X, Xiong A. Cardiovascular disease in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis of observational studies. Autoimmun Rev. 2024 Oct;23(10):103614. doi: 10.1016/j.autrev.2024.103614. Epub 2024 Aug 31. PMID: 39222675. (JCR分区：Q1)
3. Xiong A, Yang G, Song Z, Xiong C, Liu D, Shuai Y, He L, Zhang L, Guo Z, Shuai S. Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series. Ther Adv Neurol Disord. 2021 Mar 12;14:1756286421998918. doi: 10.1177/1756286421998918. PMID: 33786066; PMCID: PMC7958167. (JCR分区：Q1)
4. Xiang Q, Cao Y, Song Z, Chen H, Hu Z, Zhou S, Zhang Y, Cui H, Luo J, Qiang Y, Wang Y, Shuai S, Yang Y, Yang M, Wei X, Xiong A. Cyclophosphamide for Treatment of Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-analysis. Clin Ther. 2022 Aug;44(8):1058-1070. doi: 10.1016/j.clinthera.2022.06.008. Epub 2022 Jul 22. PMID: 35872028. (JCR分区：Q2)
5. Xiang Q, Yang M, Luo W, Cao Y, Shuai S, Wei X, Xiong A. Combined glucocorticoids and cyclophosphamide in the treatment of Graves' ophthalmopathy: a systematic review and meta-analysis. BMC Endocr Disord. 2024 Jan 26;24(1):12. doi: 10.1186/s12902-024-01545-0. PMID: 38273269; PMCID: PMC10811849. (JCR分区：Q2)
6. Deng R, Yuan G, Ye Y, Luo W, Zhong J, Wang H, Wei X, Luo X, Xiong A. Qualitative evaluation of connective tissue disease with cytomegalovirus infection: A meta-analysis of case reports. Semin Arthritis Rheum. 2024 Apr;65:152396. doi: 10.1016/j.semarthrit.2024.152396. Epub 2024 Feb 5. PMID: 38340610. (JCR分区：Q1)
7. Xiong A, Zhou S, Liu C, Hu Z, Xie C, Zheng X, Luo X. Vitamin D levels in idiopathic inflammatory myopathy patients: a meta-analysis. Postgrad Med. 2024 Mar;136(2):141-149. doi: 10.1080/00325481.2024.2325335. Epub 2024 Mar 4. PMID: 38420733. (JCR分区：Q1)
8. Xiong A, Luo W, Tang X, Cao Y, Xiang Q, Deng R, Shuai S. Risk factors for invasive fungal infections in patients with connective tissue disease: Systematic review and meta-analysis. Semin Arthritis Rheum. 2023 Dec;63:152257. doi: 10.1016/j.semarthrit.2023.152257. Epub 2023 Aug 22. PMID: 37633041. (JCR分区：Q1)
9. Xiong A, Cao Y, Xiang Q, Song Z, Zhang Y, Zhou S, Qiang Y, Chen H, Hu Z, Cui H, Luo J, Wang Y, Yang Y, Yang M, Shuai S. Angiotensin-converting enzyme inhibitors prior to scleroderma renal crisis in systemic sclerosis: A systematic review and meta-analysis. J Clin Pharm Ther. 2022 Jun;47(6):722-731. doi: 10.1111/jcpt.13621. Epub 2022 Mar 1. PMID: 35233779. (JCR分区：Q3)
10. Xiong A, Xiang Q, Cao Y, Shuai S. Cyclophosphamide: a Therapeutic Option for Amyotrophic Lateral Sclerosis. J Neuroimmune Pharmacol. 2022 Dec;17(3-4):423-424. doi: 10.1007/s11481-021-10032-5. Epub 2021 Nov 19. PMID: 34797487. (JCR分区：Q2)
11. Cao Y, Xiang Q, Hu Z, Shuai S, Xiong A. Tacrolimus, cyclosporine, and grapefruit: Friends or foes? Transpl Immunol. 2022 Jun;72:101584. doi: 10.1016/j.trim.2022.101584. Epub 2022 Mar 20. PMID: 35322792. (JCR分区：Q3)
12. Luo W, Tu H, Xiong A. Response to "Do not ignore another risk factor of invasive fungal infections in patients with connective tissue disease". Semin Arthritis Rheum. 2024 Apr;65:152395. doi: 10.1016/j.semarthrit.2024.152395. Epub 2024 Jan 29. PMID: 38308929. (JCR分区：Q1)
13. Xiong A, Li S, Dou X, Yao Y. Cyclophosphamide in refractory autoimmune hepatitis and autoimmune hepatitis coexisting extrahepatic autoimmune disorders. Am J Med Sci. 2024 Nov;368(5):446-454. doi: 10.1016/j.amjms.2024.06.007. Epub 2024 Jun 12. PMID: 38876435. (JCR分区：Q2)
14. Xiong A, Cui H, Deng R, Wei X. Cyclophosphamide in the Treatment of Systemic Lupus Erythematosus-related Guillain-Barré Syndrome: A Systematic Review of Case Reports. J Neuroimmune Pharmacol. 2023 Sep;18(3):285-293. doi: 10.1007/s11481-023-10075-w. Epub 2023 Jun 30. PMID: 37391567. (JCR分区：Q2)
15. Xiong A, Xiong C, Yang G, Shuai Y, Liu D, He L, Guo Z, Zhang L, Liu Y, Yang Y, Cui B, Shuai S. The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis. Front Med (Lausanne). 2021 Mar 1;8:609924. doi: 10.3389/fmed.2021.609924. PMID: 33732714; PMCID: PMC7956966. (JCR分区：Q1)
16. Xiong A, Hu Z, Zhou S, Qiang Y, Song Z, Chen H, Xiang Q, Zhang Y, Cao Y, Cui H, Luo J, Wang Y, Yang Y, Cui B, Li M, Shuai S. Cardiovascular events in adult polymyositis and dermatomyositis: a meta-analysis of observational studies. Rheumatology (Oxford). 2022 Jul 6;61(7):2728-2739. doi: 10.1093/rheumatology/keab851. PMID: 34791063. (JCR分区：Q1)
17. Xiong A, Liu Q, Zhong J, Cao Y, Xiang Q, Hu Z, Zhou S, Song Z, Chen H, Zhang Y, Cui H, Shuai S. Increased risk of mortality in systemic sclerosis-associated pulmonary hypertension: a systemic review and meta-analysis. Adv Rheumatol. 2022 Mar 30;62(1):10. doi: 10.1186/s42358-022-00239-2. PMID: 35354494. (JCR分区：Q3)
18. Xiong A, Qiang Y, Cao Y, Shuai Y, Chen H, Xiang Q, Hu Z, Song Z, Zhou S, Zhang Y, Cui H, Wang Y, Luo J, Shuai S, Yang Y. The therapeutic efficacy and safety of intravenous immunoglobulin in dermatomyositis and polymyositis: A systematic review and meta-analysis. Mod Rheumatol. 2023 Apr 13;33(3):533-542. doi: 10.1093/mr/roac057. PMID: 35660927.(JCR分区：Q3)
19. Xiong A, Liu D, Chen H, Yang G, Xiong C, Shuai Y, He L, Guo Z, Zhang L, Yang Y, Cui B, Shuai S. The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies. Front Pharmacol. 2021 Sep 16;12:620340. doi: 10.3389/fphar.2021.620340. PMID: 34603013; PMCID: PMC8481770. (JCR分区：Q1)
20. Xiong A, Liu Y. Targeting Hypoxia Inducible Factors-1α As a Novel Therapy in Fibrosis. Front Pharmacol. 2017 May 30;8:326. doi: 10.3389/fphar.2017.00326. PMID: 28611671; PMCID: PMC5447768. (JCR分区：Q1)
21. Zhao Y, Chen J, Xiong A. Innovative use of telitacicept in Ehlers-Danlos syndrome. Med Clin (Barc). 2024;162(3):141-142. doi:10.1016/j.medcli.2023.06.043 (JCR分区：Q2)
赋能与精进：独立病区提供全方位照护
科室除了配备“高+中+初级”阶梯式医生团队外，此次升级的另一大亮点是风湿免疫科独立护理单元的正式设立。这意味着风湿免疫科患者将获得更加专业化、精细化的护理服务。
独立的护理团队将全部由经过风湿免疫病专科培训的护士组成，她们深刻理解风湿免疫病患者的特殊需求，能够为患者提供包括慢病管理、用药指导、康复训练、心理疏导及健康教育在内的全方位、一站式优质护理服务。这一变革将极大提升患者的就医体验和治疗效果，是科室迈向“以患者为中心”的精准医疗和整体照护模式的关键一步。
新旧交接，传承的是使命与责任;薪火相传，不变的是仁心与仁术。内江市第一人民医院风湿免疫科将在医院领导班子的指导下，站在新的历史起点，依托独立护理单元的专业支撑，秉承医院的优良传统，不断精进医术、优化服务，努力建设成为技术领先、服务一流、患者信赖的区域性风湿免疫诊疗中心，为守护广大人民群众的健康贡献新的、更大的力量!
